Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects-Reference-Cited by-同舟云学术

Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects

Published:2020-11-09 Issue:1 Volume:46 Page:71-83
ISSN:0378-7966
Container-title:European Journal of Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Eur J Drug Metab Pharmacokinet

Author:

Tompson Debra J.^ORCID,Davies Carwyn^ORCID,Scott Nicola E.,Cannons Edward P.^ORCID,Kostapanos Michalis^ORCID,Gross Annette S.^ORCID,Powell Marcy^ORCID,Ino Hiroko^ORCID,Shimamura Ryutaro^ORCID,Ogura Hirofumi^ORCID,Nagakubo Takashi^ORCID,Igarashi Harue^ORCID,Nakano Atsushi^ORCID

Funder

GlaxoSmithKline

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s13318-020-00652-2.pdf

Reference19 articles.

1. Weisel K, Scott NE, Tompson DJ, Votta BJ, Madhavan S, Povey K, et al. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers. Pharmacol Res Perspect. 2017. https://doi.org/10.1002/prp2.365.

2. Zhou W, Yuan J. Necroptosis in health and diseases. Semin Cell Dev Biol. 2014;35:14–23.

3. Kopalli SR, Kang T-B, Koppula S. Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders—a review of the current literature and patents. Expert Opin Ther Patents. 2016;26(11):1239–56.